New Data for KEYTRUDA® (pembrolizumab) in Combination with Talimogene Laherparepvec, Dabrafenib Plus Trametinib, or Low-Dose Ipilimumab in Advanced Melanoma Presented at 2016 ASCO Annual Meeting

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced findings from three separate studies evaluating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in combination with other treatment regimens including talimogene laherparepvec, dabrafenib plus trametinib, or low-dose ipilimumab in patients with advanced melanoma. Language: English Contact: MerckMedia Contacts:Pamela Eisele, 267-305-3558orAn Phan, 908-255-6325orInvestor Contacts:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News #Merck #MRK $MRK ASCO Keytruda MSD Source Type: news

Related Links:

This study provides important information on the preparation of C. nutans and its effectiveness as an anticancer concoction for regular consumption.
Source: Journal of Herbal Medicine - Category: Complementary Medicine Source Type: research
Authors: Wadhwa R, Li L, Singh R, Wang J, Gao R, Nigam N, Forestier S, Ando N, Kaul SC Abstract Skin color/pigmentation is regulated through melanogenesis process in specialized melanin-producing cells, melanocytes, involving multiple signaling pathways. It is highly influenced by intrinsic and extrinsic factors such as oxidative, ultraviolet radiations and other environmental stress conditions. Besides determining the color, it governs response and tolerance of skin to a variety of environmental stresses and pathological conditions including photodamage, hyperpigmentation, and skin cancer. Depigmenting reagents ha...
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research
Authors: Niranjan A, Lunsford LD, Ahluwalia MS Abstract The most common primary cancers that metastasize to the brain are lung cancer, breast cancer, and melanoma. The established management approaches for brain metastasis include stereotactic radiosurgery, fractionated radiation therapy, and surgical resection. In the past the role of medical therapies in brain metastases was limited. In the last decade, our understanding of molecular drivers of brain metastases and CNS penetration of drugs across the blood-brain barrier has improved. The molecular targeted tyrosine kinase inhibitors have shown effectiveness in br...
Source: Progress in Neurological Surgery - Category: Neurosurgery Tags: Prog Neurol Surg Source Type: research
We would like to comment on Harbour and associates ’ American Ophthalmological Society thesis “Are risk factors for growth of choroidal nevi associated with malignant transformation? Assessment with a validated genomic biomarker.”1 The authors found that of the many clinical features associated with “malignant transformation” of a melanocy tic tumor, only 2, tumor thickness greater than 2.25 mm and patient age (over 60), are significant. There are likely a few exceptions to this, such as diffuse melanoma.
Source: American Journal of Ophthalmology - Category: Opthalmology Authors: Tags: Correspondence Source Type: research
ConclusionUrgent action is needed to promote skin cancer prevention. This study adds to the evidence that melanoma prevention strategies should preferentially target tanning attitudes rather than skin cancer knowledge.
Source: Irish Journal of Medical Science - Category: General Medicine Source Type: research
AbstractCheckpoint blockade immunotherapy is now a first-line treatment option for patients with melanoma. Despite achieving objective responses in about half of patients, the exact immune mechanisms elicited and those required for therapeutic success have not been clearly identified. Insight into these mechanisms is key for improving outcomes in a broader range of cancer patients. We used a murine melanoma model to track responses by different subsets of tumor-infiltrating lymphocytes (TIL) during checkpoint blockade immunotherapy. Tumors from treated mice had increased frequencies of both CD4+ and CD8+ T cells, which als...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
Authors: Sugiyama A, Schartl M, Naruse K Abstract Melanocytic tumors in Xiphophorus melanoma receptor kinase (xmrk)-transgenic Carbio and HB11A strains of medaka were examined histopathologically at 7 months post-hatching. Medaka of both strains developed melanocytic tumors with a penetrance of 100%. In both strains, neoplastic cells containing intracytoplasmic melanin pigment granules showed significant invasive growth patterns. In addition, epithelioid neoplastic cells were arranged in solid nests, and spindle neoplastic cells were arranged in interlacing streams and bundles. Nuclear atypia, anisokaryosis, cellul...
Source: Journal of Toxicologic Pathology - Category: Toxicology Tags: J Toxicol Pathol Source Type: research
This study might provide a new insight to understand the pathogenesis of melanoma and possibly contributed to development of therapeutic approaches for melanoma.Graphical abstract
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
ConclusionThis is the first report to demonstrate the effects of WSB2 on melanoma cell function. WSB2 has potential to become a new therapeutic target in patients with melanoma.
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
The prognosis of metastatic melanoma has not changed throughout the 20th century. However, in the last decade, we have witnessed a continuous improvement in survival, with many long-term survivors. These results are largely because of the simultaneous development of the knowledge in the biology of metastatic malignant melanoma and of the relationship between the disease and the host’s immune system that allowed the development of effective new treatments. In this overview, we summarize the therapies available today, their biological rationale, and the research field currently under investigation divided into three ma...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: REVIEW ARTICLES Source Type: research
More News: Cancer & Oncology | Melanoma | Merck | Pharmaceuticals | Skin Cancer | Study | Yervoy